Burkitt’s and Burkitt-like Lymphoma

Current Treatment Options in Oncology

Volumn 3, Issue 4, 2002, Pages 291-305

  Evens, Andrew M ^a   Gordon, Leo I ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Allopurinol; Clin Oncol; Lymphoma; Main Drug Interaction; Main Side Effect

Indexed keywords

ANTINEOPLASTIC AGENT;

B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CLINICAL TRIAL; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, AIDS-RELATED;

EID: 0036675208     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0029-9     Document Type: Article

References (75)

1. Lee EJ, Petroni GR, Schiffer CA, et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014–4022.
2. Magrath I, Adde M, Shad A, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925–934.
3. Adde M, Shad A, Venzon D, et al.: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998, 25:33–39.
4. Patte C, Auperin A, Michon J, et al.: The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370–3379. DOI: 10.1182/blood.V97.11.3370
5. Kantarjian HM, O’Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547–561.
6. Larson RA, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85:2025–2037.
7. Fenaux P, Bourhis JH, Ribrag V: Burkitt’s acute lymphocytic leukemia (L3ALL) in adults. Hematol Oncol Clin North Am 2001, 15:37–50. DOI: 10.1016/S0889-8588(05)70199-4
8. Harris NL, Jaffe ES, Stein H, et al.: A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361–1392.
9. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849.
10. Braziel RM, Arber DA, Slovak ML, et al.: The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001, 97:3713–3720. DOI: 10.1182/blood.V97.12.3713
11. Wright DH: What is Burkitt’s lymphoma and when is it endemic? Blood 1999, 93:758.
12. Hecht JL, Aster JC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol 2000, 18:3707–3721.
13. Ziegler JL: Chemotherapy of Burkitt’s lymphoma. Cancer 1972, 30:1534–1540. DOI: 10.1002/1097-0142(197212)30:6<1534::AID-CNCR2820300619>3.0.CO;2-6
14. Ziegler JL: Treatment results of 54 American patients with Burkitt’s lymphoma are similar to the African experience. N Engl J Med 1977, 297:75–80. DOI: 10.1056/NEJM197707142970202
15. Bowman WP, Shuster JJ, Cook B, et al.: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996, 14:1252–1261.
16. Lerede T, Bassan R, Rossi A, et al.: Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt’s lymphoma. Haematologica 1996, 81:442–449.
17. Clarkson BD, Gee T, Arlin ZA, et al.: Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. Crit Rev Oncol Hematol 1986, 4:221–248.
18. Hoelzer D, Ludwig WD, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495–508.
19. Patte C, Michon J, Frappaz D, et al.: Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994, 7:339–348. DOI: 10.1016/S0950-3536(05)80206-9
20. Atra A, Gerrard M, Hobson R, et al.: Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin’s lymphoma (B-NHL): results of the UKCCSG 9003 protocol. Br J Cancer 1998, 77:2281–2285.
21. McMaster ML, Greer JP, Wolff SN, et al.: Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin’s lymphoma. Cancer 1991, 68:233–241. DOI: 10.1002/1097-0142(19910715)68:2<233::AID-CNCR2820680203>3.0.CO;2-Q
22. Pees HW, Radtke H, Schwamborn J, Graf N: The BFMprotocol for HIV-negative Burkitt’s lymphomas and L3 ALL in adult patients: a high chance for cure. Ann Hematol 1992, 65:201–205. DOI: 10.1007/BF01703945
23. Straus DJ, Wong GY, Liu J, et al.: Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt’s type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am J Med 1991, 90:328–337.
24. Todeschini G, Tecchio C, Degani D, et al.: Eighty-one percent event-free survival in advanced Burkitt’s lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997, 8:77–81. DOI: 10.1023/A:1008214203225
25. Weintraub M, Adde MA, Venzon DJ, et al.: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935–940.
26. Atra A, Gerrard M, Hobson R, et al.: Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol 2001, 112:965–968. DOI: 10.1046/j.1365-2141.2001.02647.x
27. Philip T, Hartmann O, Pinkerton R, et al.: Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood 1993, 81:2003–2006.
28. Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664–674.
29. Sweetenham JW, Pearce R, Taghipour G, et al.: Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996, 14:2465–2472.
30. Nademanee A, Molina A, O’Donnell MR, et al.: Results of high-dose therapy and autologous bone marrow/ stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997, 90:3844–3852.
31. Nademanee A, Molina A, Dagis A, et al.: Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin’s lymphoma. Clin Lymphoma 2000, 1:46–54. DOI: 10.3816/CLM.2000.n.004
32. Slavin S, Naparstek E, Nagler A, et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87:2195–2204.
33. Troussard X, Leblond V, Kuentz M, et al.: Allogeneic bone marrow transplantation in adults with Burkitt’s lymphoma or acute lymphoblastic leukemia in first complete remission. J Clin Oncol 1990, 8:809–812.
34. Ungkanont A, Mongkonsritrakoon W, Jootar S, Srichaikul T: Allogeneic stem cell transplantation in a patient with refractory Burkitt’s lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant 2000, 26:1351–1354. DOI: 10.1038/sj.bmt.1702730
35. Bureo E, Ortega JJ, Munoz A, et al.: Bone marrow transplantation in 46 pediatric patients with non- Hodgkin’s lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995, 15:353–359.
36. Spina M, Tirelli U, Zagonel V, et al.: Burkitt’s lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer 1998, 82:766–774. DOI: 10.1002/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V
37. Kirk O, Pedersen C, Cozzi-Lepri A, et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001, 98:3406–3412. DOI: 10.1182/blood.V98.12.3406
38. Ratner L, Lee J, Tang S, et al.: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171–2178.
39. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142—low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colonystimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998, 16:3601–3606.
40. Davi F, Delecluse HJ, Guiet P, et al.: Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non- Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J Clin Oncol 1998, 16:3788–3795.
41. Tirelli U, Spina M, Jaeger U, et al.: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002, 159:149–153.
42. Tirelli U, Bernardi D: Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2001, 37:1320–1324. DOI: 10.1016/S0959-8049(01)00106-X
43. Thiessard F, Morlat P, Marimoutou C, et al.: Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d’Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Cancer 2000, 88:1696–1702. DOI: 10.1002/(SICI)1097-0142(20000401)88:7<1696::AID-CNCR25>3.0.CO;2-L
44. Matthews GV, Bower M, Mandalia S, et al.: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000, 96:2730–2734.
45. Krishnan A, Molina A, Zaia J, et al.: Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001, 98:3857–3859. DOI: 10.1182/blood.V98.13.3857
46. Campbell P, Iland H, Gibson J, Joshua D: Syngeneic stem cell transplantation for HIV-related lymphoma. Br J Haematol 1999, 105:795–798. DOI: 10.1046/j.1365-2141.1999.01422.x
47. Molina A, Krishnan AY, Nademanee A, et al.: High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non- Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000, 89:680–689. DOI: 10.1002/1097-0142(20000801)89:3<680::AID-CNCR25>3.0.CO;2-W
48. Gabarre J, Azar N, Autran B, et al.: High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000, 355:1071–1072. DOI: 10.1016/S0140-6736(00)02041-9
49. Levine AM, Seneviratne L, Tulpule A: Incidence and management of AIDS-related lymphoma. Oncology (Huntingt) 2001, 15:629–639.
50. Vaccher E, Tirelli U, Spina M, et al.: Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin’s lymphomas: a single-institute study of 96 patients. J Clin Oncol 1996, 14:2217–2223.
51. Jones DP, Mahmoud H, Chesney RW: Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995, 9:206–212. DOI: 10.1007/BF00860751
52. Flombaum CD: Metabolic emergencies in the cancer patient. Semin Oncol 2000, 27:322–334.
53. Holland P, Holland NH: Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 1968, 72:358–366. DOI: 10.1016/S0022-3476(68)80209-4
54. Hogan DK, Rosenthal LD: Oncologic emergencies in the patient with lymphoma. Semin Oncol Nurs 1998, 14:312–320. DOI: 10.1016/S0749-2081(98)80009-0
55. Smalley RV, Guaspari A, Haase-Statz S, et al.: Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000, 18:1758–1763.
56. Pui CH: Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001, 38:13–21. DOI: 10.1016/S0037-1963(01)90039-3
57. Link MP, Donaldson SS, Berard CW, et al.: Results of treatment of childhood localized non-Hodgkin’s lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990, 322:1169–1174. DOI: 10.1056/NEJM199004263221701
58. Link MP, Shuster JJ, Donaldson SS, et al.: Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 1997, 337:1259–1266. DOI: 10.1056/NEJM199710303371802
59. Miron I, Frappaz D, Brunat-Mentigny M, et al.: Initial management of advanced Burkitt lymphoma in children: is there still a place for surgery? Pediatr Hematol Oncol 1997, 14:555–561. DOI: 10.3109/08880019709030912
60. Shamberger RC, Weinstein HJ: The role of surgery in abdominal Burkitt’s lymphoma. J Pediatr Surg 1992, 27:236–240. DOI: 10.1016/0022-3468(92)90319-3
61. Thieblemont C, Mayer A, Dumontet C, et al.: Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab 2002, 87:105–111. DOI: 10.1210/jc.87.1.105
62. Kemeny MM, Magrath IT, Brennan MF: The role of surgery in the management of American Burkitt’s lymphoma and its treatment. Ann Surg 1982, 196:82–86. DOI: 10.1097/00000658-198207000-00017
63. Dechambenoit G, Piquemal M, Giordano C, et al.: Spinal cord compression resulting from Burkitt’s lymphoma in children. Childs Nerv Syst 1996, 12:210–214. DOI: 10.1007/BF00301252
64. Witzig TE: Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001, 48:S91-S95. DOI: 10.1007/s002800100312
65. Thomas DA: Rituximab and hyper-CVAD for adult Burkitt’s (BL) or Burkitt-like (BLL) leukemia or lymphoma. Blood 2001:a3342.
66. Macpherson N, Lesack D, Klasa R, et al.: Small noncleaved, non-Burkitt’s (Burkit-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999, 17:1558–1567.
67. Bemark M, Neuberger MS: The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt’s lymphoma line. Oncogene 2000, 19:3404–3410. DOI: 10.1038/sj.onc.1203686
68. Hu HM, Arcinas M, Boxer LM: A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt’s lymphoma. J Biol Chem 2002, 277:9819–9824. DOI: 10.1074/jbc.M111426200
69. Madisen L, Krumm A, Hebbes TR, Groudine M: The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Mol Cell Biol 1998, 18:6281–6292.
70. Sommer A, Hilfenhaus S, Menkel A, et al.: Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol 1997, 7:357–365. DOI: 10.1016/S0960-9822(06)00183-7
71. Luscher B: Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001, 277:1–14. DOI: 10.1016/S0378-1119(01)00697-7
72. Yin X, Landay MF, Han W, et al.: Dynamic in vivo interactions among Myc network members. Oncogene 2001, 20:4650–4664. DOI: 10.1038/sj.onc.1204606
73. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503–511. DOI: 10.1038/35000501
74. Chan WC, Huang JZ: Gene expression analysis in aggressive NHL. Ann Hematol 2001, 80:B38-B41. DOI: 10.1007/s002770000222
75. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat Med 2002, 8:68–74. DOI: 10.1038/nm0102-68